FibroScan® Probes
Fit the patient morphology with the appropriated probe
The complete non-invasive solution for liver disease management
Powered by LSM by VCTE™, CAP™* and SSM by VCTE™ as part of an overall assessment of the liver.
The new spleen stiffness measurement (SSM by VCTE™) and the embedded ultrasound localization system enable risk stratification of patients with advanced chronic liver disease and portal hypertension.
SSM by VCTE™ is a unique, patented and validated new marker for Spleen Stiffness Measurement. 109+ peer-reviewed publications support the use of SSM by VCTE™.
LSM by VCTE™ is unique, patented and validated for Liver Stiffness Measurement1. 3,245 peer-reviewed publications support the use of LSM by VCTE™.
CAP™ is unique patented and validated for liver disease management. 822 international peer-reviewed publications support the use of CAP™.
FibroScan® 630 Expert Indications for Use
The FibroScan® 630 is intended to provide shear wave speed measurements and estimates of tissue stiffness as well as ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body. The Shear wave speed and stiffness measurements may be used as an aid to clinical management of adult patients with liver disease. The FibroScan® 630 is indicated for non-invasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as determining a 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter). The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver. Shear wave speed and stiffness, and CAP* may be used as an aid in the clinical management of pediatric patients with liver disease. FibroScan® 630 (Expert) is also indicated for noninvasive measurement in the spleen of 100 Hz shear wave speed and estimates of stiffness that may be used as an aid to diagnosis, monitoring and clinical management of adult patients with liver disease, as part of an overall assessment of the liver.
* CAP for pediatric patients with liver disease is only available with SmartExam capability.
FAST and Interpretation Guide are Non-Device CDS (Clinical Decision Support) that meet all parts of the 4 sections 520(o)(1)(E) criteria.
References are available in our bibliography.
Fit the patient morphology with the appropriated probe
Enhance FibroScan® liver disease assessment with biological markers
Optimize clinical workflows with real-time secure data transmission
Enhance your FibroScan® capabilities for improved management of fatty liver patients